Snehal Patel Acquires 1,800 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel bought 1,800 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was purchased at an average cost of $13.75 per share, with a total value of $24,750.00. Following the transaction, the chief executive officer now directly owns 5,550,002 shares in the company, valued at approximately $76,312,527.50. This represents a 0.03 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Thursday, January 2nd, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $11.97 per share, for a total transaction of $23,940.00.
• On Monday, December 30th, Snehal Patel acquired 3,200 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $11.12 per share, with a total value of $35,584.00.

Greenwich LifeSciences Price Performance

NASDAQ:GLSI opened at $13.35 on Friday. The firm’s 50-day moving average price is $13.15 and its 200-day moving average price is $14.13. The company has a market capitalization of $175.49 million, a PE ratio of -16.69 and a beta of 1.66. Greenwich LifeSciences, Inc. has a 1-year low of $8.00 and a 1-year high of $21.44.

Institutional Investors Weigh In On Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of GLSI. Geode Capital Management LLC lifted its holdings in shares of Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after purchasing an additional 5,861 shares during the last quarter. State Street Corp raised its stake in Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after buying an additional 3,005 shares during the last quarter. Garden State Investment Advisory Services LLC bought a new stake in Greenwich LifeSciences in the third quarter worth $253,000. Bank of New York Mellon Corp purchased a new stake in shares of Greenwich LifeSciences in the second quarter worth $264,000. Finally, Barclays PLC increased its holdings in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after acquiring an additional 6,538 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.